Vaccine Stratification and Monitoring
Apply PSI as correlates to cancer vaccine patient survival and outcome
Discover biomarkers of response by uncovering functional immune cell subsets which correlate to outcome.
How our Award-Winning IsoLight Single-Cell System is Making a Difference
Solution
IsoPlexis stratifies higher response rates based on PSI
Finding
Upregulation of Polyfunctional strength ratio (PSR) was correlative to overall survival
Follow Our Data
See the latest published data in Vaccines and Immunology Research
GVAX vaccination enhances polyfunctionality and PSI in CD4+ T cells of patients with pancreatic cancer. Polyfunctional CD4+ T cells were evaluated by 24-hour stimulation of anti-CD3/CD28.
An average increase of polyfunctional CD4+ T cells was detected in patients after GVAX treatment. The upregulated PSI of CD4+ T cells by the vaccine was predominated by effector proteins that are associated with antitumor immunity including Granzyme B, IFN-g, MIP-1a and TNF-b. The data was averaged from 5 patients.1
Solution
Detect Critical Differences
Single-cell analysis identifies a significant association of CD4+ PSI fold change (post/pre vaccination) with overall survival (OS) of patients with pancreatic cancer after GVAX treatment. Blood was collected from patients before and 10-25 days after GVAX vaccination.
The post- versus pre-vaccination fold-change of PSI of CD4+ T cells was significantly associated with patient OS (P=0.001), indicating a potential of PSI in predicting GVAX vaccine efficacy and prognostic outcomes of patients.1
[1] Reference: Zhou et al, SITC Annual Meeting 2018